Active Filter(s):
Details:
EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds reach complete healing.
Lead Product(s): EX-02
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: MediWound
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 11, 2023